Skip to content
Screener

Aclaris Therapeutics ACRS Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$3.3MBeat by $1.2M
EPS-$0.12Beat by $0.01
Revenue estimate$2.1M
EPS estimate-$0.13

Next report

Nov 5, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$0.16

Financials

Q3 2025

Income statement

See full
Revenue$3.3M-24.1%
Gross profit$2.8M-25.2%
Operating income-$17.1M-63.8%
Net income-$14.6M-92.6%
EPS (diluted)-$0.12-9.1%

Balance sheet

See full
Cash & equivalents$25.3M-47.0%
Total debt$2.2M-17.2%
Total equity$120.1M-7.7%
Total assets$175.5M-3.8%

Cash flow

See full
Operating cash flow-$10.9M—
CapEx$23.0K—
Free cash flow-$11.0M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$205.83M+151%
Enterprise value$182.82M+393%
P/S13.1×+10.0×

Profitability

See full
Gross margin85.6%-4.0pp
Operating margin-973.9%-1,237pp
Net margin-900%-1,096pp
FCF margin-273.2%—

Returns & leverage

See full
Return on equity-113.2%-161pp
Debt / equity0×0.0×
Current ratio3.9×-3.1×

FAQ

When did Aclaris Therapeutics report Q3 2025 earnings?
Aclaris Therapeutics (ACRS) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Aclaris Therapeutics's Q3 2025 revenue and EPS?
Aclaris Therapeutics reported revenue of $3.3M and eps of $-0.12 for Q3 2025.
Did Aclaris Therapeutics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $2.1M by $1.2M. EPS beat the consensus estimate of $-0.13 by $0.01.
How did Aclaris Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 24.1% from $4.3M a year earlier and eps declined 9.1% from $-0.11.
Where can I find Aclaris Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-107353) and the 10-Q periodic report (0001104659-25-107788) directly on SEC EDGAR. The filing index links above go to sec.gov.